Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal‑regulated kinase signaling pathway

Li,Mengting; He,Yulin; Peng,Cheng; Xie,Xiaofang; Hu,Guanying

doi:10.3892/ol.2018.9267

Erianin inhibits human cervical cancer cell through regulation of tumor protein p53 via the extracellular signal‑regulated kinase signaling pathway

Authors:
- Mengting Li
- Yulin He
- Cheng Peng
- Xiaofang Xie
- Guanying Hu
View Affiliations

Affiliations: State Key Laboratory Breeding Base of Systematic Research, Development and Utilization of Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan 611137, P.R. China
Published online on: August 3, 2018 https://doi.org/10.3892/ol.2018.9267
Pages: 5006-5012
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Erianin, a natural bibenzyl compound, is present in Dendrobium chrysotoxum Lindl. (commonly known as Shihu in China), which is used as an antipyretic and analgesic in traditional Chinese medicine, and has been reported to exert inhibitory effects on cancer cells in vitro. Cervical cancer is the third‑most common cancer in women worldwide, and has the highest morbidity rate of gynecological malignancies. Thus, the identification of effective chemotherapeutical agents to treat this disease is urgent. The aim of the present study was to elucidate the biological functions and molecular mechanism of erianin on HeLa cells. Cellular proliferation was assessed using an MTT assay and flow cytometry assay with propidium iodide (PI) staining. Apoptosis rates were observed using a high content screening system via annexin V‑fluorescein isothiocyanate/PI double staining, and measured by flow cytometry. The protein levels of tumor protein p53, extracellular signal‑regulated kinase 1/2 (ERK1/2), caspase‑3, B‑cell lymphoma‑2 (Bcl‑2) and Bcl‑2‑associated X (Bax) were assessed by western blot analysis. Erianin inhibited the growth of HeLa cells and induced apoptosis in a dose‑ and time‑dependent manner, inducing cell cycle arrest at the G2/M stage. Erianin treatment also increased the expression of Bax and caspase‑3, but decreased levels of Bcl‑2 and phosphorylated‑ERK1/2. Cells treated with paclitaxel were regarded as the positive group. Together, the results of the present study indicated that erianin could be considered as an effective drug candidate; in HeLa cells it inhibited cellular proliferation and promoted apoptosis via regulation of the ERK1/2 signaling and mitochondrial‑based apoptosis pathways. Thus, erianin has the promise to be developed further for cervical cancer therapy.

View Figures

View References

1	Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A and Galazios G: Cervical cancer: Screening, diagnosis and staging. J BUON. 21:320–325. 2016.PubMed/NCBI
2	Bonneau C, Perrin M, Koskas M, Genin AS and Rouzier R: Epidemiology and risk factors for cancer of the uterus. Rev Prat. 64:774–779. 2014.(In French). PubMed/NCBI
3	Castle PE and Maza M: Prophylactic HPV vaccination: Past, present, and future. Epidemiol Infect. 144:449–468. 2016. View Article : Google Scholar : PubMed/NCBI
4	Tang J and Hao F: The present situation and the future of vaccines for cervical cancer. Immunol J. 26:546–550. 2010.
5	Chinese Pharmacopoeia Committee, . Pharmacopoeia of China. Chin Med Sci Technol Press; pp. 1–93. 2015
6	Ng TB, Liu F and Wang ZT: Antioxidative activity of natural products from plants. Life Sci. 66:709–723. 2000. View Article : Google Scholar : PubMed/NCBI
7	Ma GX, Xu GJ and Xu LS: Inhibitory effects of Dendrobium chrysotoxum and its constituents on the mouse HePA and ESC. J Chin Pharm Univ. 25:188–189. 1994.
8	Li YM, Wang HR and Liu GQ: Erianin induces apoptosis in human leukemia HL-60 cells. Acta Pharmacol Sin. 22:1018–1022. 2001.PubMed/NCBI
9	Ma GX and LeBlanc GA: The activity of erianin and chrysotoxine from Dendrobium chrysotoxum to reverse multidrug resistance in B16/hMDR-1 Cells. J Chin Pharm Sci. 7:142–146. 1998.
10	Zhang W, Yuan W, Xu N, Li J and Chang W: Icariin improves acute kidney injury and proteinuria in a rat model of pregnancy-induced hypertension. Mol Med Rep. 16:73982017. View Article : Google Scholar : PubMed/NCBI
11	Cerami EG, Gross BE, Demir E, Rodchenkov I, Babur O, Anwar N, Schultz N, Bader GD and Sander C: Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 39:D685–D690. 2011. View Article : Google Scholar : PubMed/NCBI
12	Wawryk-Gawda E, Chylińska-Wrzos P, Lis-Sochocka M, Chłapek K, Bulak K, Jędrych M and Jodłowska-Jędrych B: P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 251:525–533. 2014. View Article : Google Scholar : PubMed/NCBI
13	Yang T, Xu F, Sheng Y, Zhang W and Chen Y: A targeted proteomics approach to the quantitative analysis of ERK/Bcl-2-mediated anti-apoptosis and multi-drug resistance in breast cancer. Anal Bioanal Chem. 408:7491–7503. 2016. View Article : Google Scholar : PubMed/NCBI
14	Robles AI and Harris CC: p53-mediated apoptosis and genomic instability diseases. Acta Oncol. 40:696–701. 2001. View Article : Google Scholar : PubMed/NCBI
15	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
16	Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA and Fiorica JV; Gynecologic Oncology Group Study, : Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A gynecologic oncology group study. J Clin Oncol. 23:4626–4633. 2005. View Article : Google Scholar : PubMed/NCBI
17	Kurtz JE, Freyer G, Joly F, Gladieff L, Kaminski MC, Fabbro M, Floquet A, Hardy-Bessard AC, Raban N, Ray-Coquard I and Pujade-Lauraine E; GINECO Group, France, . Combined oral topotecan plus carboplatin in relapsed or advanced cervical cancer: A GINECO phase I–II trial. Anticancer Res. 32:1045–1049. 2012.PubMed/NCBI
18	Xiong Y, Liang LZ, Cao LP, Min Z and Liu JH: Clinical effects of irinotecan hydrochloride in combination with cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Gynecol Oncol. 123:99–104. 2011. View Article : Google Scholar : PubMed/NCBI
19	Peng R and Zhao CQ: Chemotherapy drugs in the application and research progress of cerical cancer treatment. Chin Pharm. 24:1143–1146. 2013.
20	Jin ZH, Liao GH and Jiang N: Clinical analyses on 91 recurrence or metastasis cases of young women cervical cancer. Pract J Cancer. 21:502–503,511. 2006.
21	Sun J, Fu X, Wang Y, Liu Y, Zhang Y, Hao T and Hu X: Erianin inhibits the proliferation of T47D cells by inhibiting cell cycles, inducing apoptosis and suppressing migration. Am J Transl Res. 8:3077–3086. 2016.PubMed/NCBI
22	Yu Z, Zhang T, Gong C, Sheng Y, Lu B, Zhou L, Ji L and Wang Z: Erianin inhibits high glucose-induced retinal angiogenesis via blocking ERK1/2-regulated HIF-1α-VEGF/VEGFR2 signaling pathway. Sci Rep. 6:343062016. View Article : Google Scholar : PubMed/NCBI
23	Su P, Wang J, An JX, Zhu Q, Lu X and Tang Y: Inhibitory effect of erianin on hepatocellular carcinoma (HCC) Huh7 cells. Chin J Appl Environ Biol. 17:662–665. 2011.
24	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011.144:646–674. View Article : Google Scholar : PubMed/NCBI
25	El-Baba C, Mahadevan V, Fahlbusch FB, Mohan SS, Rau TT, Gali-Muhtasib H and Schneider-Stock R: Thymoquinone-induced conformational changes of PAK1 interrupt prosurvival MEK-ERK signaling in colorectal cancer. Mol Cancer. 13:2012014. View Article : Google Scholar : PubMed/NCBI
26	Song X, Wang Y, Du H, Fan Y, Yang X, Wang X, Wu X and Luo C: Overexpression of HepaCAM inhibits cell viability and motility through suppressing nucleus translocation of androgen receptor and ERK signaling in prostate cancer. Prostate. 74:1023–1033. 2014. View Article : Google Scholar : PubMed/NCBI
27	Bai LX, Mao R, Wang J, Ding L, Jiang S, Gao C, Kang H, Chen X, Sun X and Xu J: ERK1/2 promoted proliferation and inhibited apoptosis of human cervical cancer cells and regulated the expression of c-Fos and c-Jun proteins. Med Oncol. 32:572015. View Article : Google Scholar : PubMed/NCBI
28	Wei H, Shenglin M, Lingbin D, et al: Experimental study of erianin inducing apotosis in gastric carcinoma SGC-7901. Chin Cancer. 17:499–501. 2008.(In Chinese).
29	Cui XQ, Su P, Zhu QY, An JX, Wang J, Wu J and Tang YX: Molecular mechanism of apoptosis of human colorectal cancer SW480 cells induced by Erianin. Chin J Appl Environ Biol. 17:512–516. 2011.
30	Hoogervorst EM, Van SH and De VA: Nucleotide excision repair- and p53-deficient mouse models in cancer research. Mutat Res. 574:3–21. 2015. View Article : Google Scholar
31	Haga S, Nakayama M, Tatsumi K, Maeda M, Imai S, Umesako S, Yamamoto H, Hilgers J and Sarkar NH: Overexpression of the p53 gene product in canine mammary tumors. Oncol Rep. 8:1215–1219. 2001.PubMed/NCBI
32	Park YK, Chi SG, Kim YW, Park HR and Unni KK: P53 mutations in Ewing's sarcoma. Oncol Rep. 8:533–537. 2001.PubMed/NCBI
33	Moskovits N, Kalinkovich A, Bar J, Lapidot T and Oren M: p53 attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res. 66:10671–10676. 2006. View Article : Google Scholar : PubMed/NCBI
34	Khan S, Chib R, Shah BA, Wani ZA, Dhar N, Mondhe DM, Lattoo S, Jain SK, Taneja SC and Singh J: A cyano analogue of boswellic acid induces crosstalk between p53/PUMA/Bax and telomerase that stages the human papillomavirus type 18 positive HeLa cells to apoptotic death. Eur J Pharmacol. 660:241–248. 2011. View Article : Google Scholar : PubMed/NCBI
35	Chen ZL, Gu PQ, Liu K, Su YJ and Gao LJ: The globular heads of the C1q receptor regulate apoptosis in human cervical squamous carcinoma cells via a p53-dependent pathway. J Transl Med. 10:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
36	Zhou MJ, Chen FZ, Chen HC, Wan XX, Zhou X, Fang Q and Zhang DZ: ISG15 inhibits cancer cell growth and promotes apoptosis. Int J Mol Med. 39:446–452. 2017. View Article : Google Scholar : PubMed/NCBI
37	Liu Y, Li L, Liu Y, Geng P, Li G, Yang Y and Song H: RECK inhibits cervical cancer cell migration and invasion by promoting p53 signaling pathway. J Cell Biochem. 4:3058–3066. 2018. View Article : Google Scholar
38	Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
39	Kaufmann SH and Vaux DL: Alterations in the apoptotic machinery and their potential role in anticancer drug resistance. Oncogene. 22:7414–7430. 2003. View Article : Google Scholar : PubMed/NCBI
40	Schmitt CA, Rosenthal CT and Lowe SW: Genetic analysis of chemoresistance in primary murine lymphomas. Nat Med. 6:1029–1035. 2000. View Article : Google Scholar : PubMed/NCBI
41	Kang MH and Reynolds CP: Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
42	Patel MR, Masood A, Patel PS and Chanan-Khan AA: Targeting the Bcl-2. Curr Opin Oncol. 21:516–523. 2009. View Article : Google Scholar : PubMed/NCBI
43	Leibowitz B and Yu J: Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther. 9:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
44	Hu Y, Ding L, Spencer DM and Núñez G: WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation. J Biol Chem. 273:33489–33494. 1998. View Article : Google Scholar : PubMed/NCBI
45	Jiang XJ and Wang XD: Cytochrome C-mediated apoptosis. AnnuRev Biochem. 73:87–106. 2014. View Article : Google Scholar
46	Peng Y, Guo C, Yang Y, Li F, Zhang Y, Jiang B and Li Q: Baicalein induces apoptosis of human cervical cancer HeLa cells in vitro. Mol Med Rep. 11:2129–2134. 2015. View Article : Google Scholar : PubMed/NCBI
47	Xu T, Pang Q, Zhou D, Zhang A, Luo S, Wang Y and Yan X: Proteomic investigation into betulinic acid-induced apoptosis of human cervical cancer HeLa cells. PLoS One. 9:e1057682014. View Article : Google Scholar : PubMed/NCBI
48	Kundranda MN and Niu J: Albumin-bound paclitaxel in solid tumors: Clinical development and future directions. Drug Des Devel Ther. 9:3767–3777. 2015. View Article : Google Scholar : PubMed/NCBI